Pfizer ( NYSE: PFE ) shares traded in the red on Friday, making it the seventh straight day of losses. The stock is down 0.43% at $27.
53. PFE has fallen 31.63% in the last 12 months and 3.
1% in the last one month. YTD, the stock has underperformed the broader S&P 500 market, which rose 13.92% as compared to the company’s YTD loss of 3.
96%. Looking at Seeking Alpha's Quant Ratings, this New York based company has a Hold rating with a score of 3.41 out of 5.
When it comes to Wall Street analysis, 16 out of 25 analysts recommend a Hold, 7 rate it as a Strong Buy and 2 rate it as a Buy. Seeking Alpha analysts have a Buy rating on the company. According to SA analyst ONeil Trader, “The headwinds for Pfizer's commercial business are dissipating and the tough year-over-year comps are finally in the rearview mirror.
With an expected return to topline growth, the addition of Seagen products and pipeline, and a healthy slate of recent and expected product launches, Pfizer is in a good position to deliver decent long-term shareholder returns. More on Pfizer Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Pfizer Inc. (PFE) CEO Albert Bourla presents at Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Pfizer: Surging Cancer Rates Will Boost Revenues CDC 'preparing for the possibility' bird flu could spread more easily Pfizer's Elrexfio buoyed by multiple myeloma survival data.
